About Transparent Peptide
Transparent Peptide evaluates U.S. telehealth programs offering GLP-1 medications, peptide therapies and longevity treatments using a published, source-based methodology.
Our mission
Transparent Peptide helps people compare telehealth programs for GLP-1 medications, peptide therapies and longevity treatments. We evaluate total cost, clinician oversight, pharmacy disclosure, medication sourcing, patient support and plan terms — and we publish the evidence behind every score so readers can check our work.
Independence and affiliation
Transparent Peptide is not fully independent, and we say so plainly. Disclosure: Transparent Peptide is published by US Peptides Partners LLC. The publisher and certain principals have financial relationships with some of the telehealth providers listed on this site, and we may earn a commission when readers use certain links. Every provider is evaluated under the same published methodology, compensation does not change any score, ranking, inclusion or editorial conclusion, and the evidence behind each score is published so readers can judge it for themselves. We publish this relationship on every page where NexLife appears. See our conflicts-of-interest policy.
How we work
Every provider is scored under a published methodology before rankings are written. Facts are captured with dates and verification status. A physician and a nurse practitioner review clinical content. Corrections are logged.
Contact
Editorial: editorial@transparrentpeptide.com. Corrections: corrections@transparrentpeptide.com. See our contact page.